Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRObiotic Therapy Examining Combinatorial Therapeutics in Multiple Sclerosis
2025-520955-10-00Phase 2Withdrawn
- Sponsor
- Military Institute of Medicine – National Research Institute
- Start
- Oct 2025
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Trilac and Lacidofil in multiple sclerosis (MS) (6 arms), sponsored by Military Institute of Medicine – National Research Institute. Primary endpoint: Annualized Relapse Rate (ARR). Planned start Oct 2025; status: withdrawn.
02
Drugs
TrilacLacidofil
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2025-520955-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520955-10-00.